| 引用本文： |
-
周振,冯立明,姚旭东,等.神经内分泌前列腺癌生物标志物与治疗靶点研究进展[J].同济大学学报（医学版）,2022,43(2):278-284. [点击复制]
- ZHOU Zhen,FENG Liming,YAO Xudong,et al.Research progress of biomarkers and therapeutic targets for neuroendocrine prostate cancer[J].Journal of Tongji University(Medical Science),2022,43(2):278-284. [点击复制]
|
|
| 摘要: |
| 神经内分泌前列腺癌(neuroendocrine prostate cancer, NEPC)是晚期前列腺癌治疗耐药的重要原因，目前临床对其早期诊断与治疗的认知仍存在不足。针对这一现状，本文回顾了NEPC近年来新出现的诊断、治疗靶点，拟为今后相关临床工作提供更加全面的诊疗参考。 |
| 关键词: 前列腺癌 神经内分泌分化 生物标志物 治疗靶点 |
| DOI：10.12289/j.issn.1008-0392.21326 |
| 通信作者: |
| 投稿时间：2021-07-27 |
| 录用日期： |
| 基金项目:国家自然科学基金面上项目(81972409、81672549)；上海市自然科学基金(15ZR1433000) |
|
| Research progress of biomarkers and therapeutic targets for neuroendocrine prostate cancer |
| ZHOU Zhen,FENG Liming,YAO Xudong,YE Lin |
| (Department of Urology, Shanghai Tenth People’s Hospital, Nanjing Medical University, Nanjing 211166, China;Department of General Surgery and Urology, Shawan People’s Hospital, Shawan 832100, Xinjiang Uygur Autonomous Region, China;Department of Urology, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai 200072, China;Department of Urology, Shanghai Tenth People’s Hospital, Nanjing Medical University, Nanjing 211166, China; Department of Urology, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai 200072, China) |
| Abstract: |
| The advanced neuroendocrine prostate cancer(NEPC) is frequently resistant to drug therapy, due to lack of its clinical awareness for early diagnosis and treatment. This article reviews the recent research progress on the diagnostic biomarkers and therapeutic targets of NEPC, to provide information for more comprehensive diagnosis and treatment of NEPC in the future. |
| Key words: prostate cancer neuroendocrine differentiation biomarkers therapeutic target |
